Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Sponsor
Getz Pharma
Study ID
NCT05359432
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
30 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Empagliflozin — DRUG
    Receiving allocated drug dosage as per clinical needs
  • Vildagliptin — DRUG
    Receiving allocated drug dosage as per clinical needs

Study Details

The aim of this study is to perform a comparison of the efficacy and safety of empagliflozin and vildagliptin in patients with Type 2 Diabetes Mellitus open labelled, multi-centric, parallel, randomized control trial In Type 2 Diabetes patients, impact of empagliflozin (10 mg once or twice daily) versus vildagliptin (50 mg once or twice daily) assessed for Efficacy \& safety parameters to be measured at both the baseline and 24-week visits.

Key Dates

Start date
Jul 1, 2020
Status verified
Apr 2022
Primary completion
Aug 10, 2021
Completion
Aug 18, 2021

Study Design

Enrollment
120 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
  • Experimental: Vildagliptin

Primary Outcome Measure

Glycosylated hemoglobin A1c (HbA1c) [ Time Frame: 24 weeks ]

Related Studies